PDCD1 and melanoma: In addition, Gide et al. demonstrated that in a group of 158 melanoma patients who received treatment with either anti-PD-1 alone or plus anti-CTLA-4, the presence of Eomes+CD69+CD45RO+ Tem cells in tumor samples was linked to a response and longer PFS [93].